PMID- 37601792
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230823
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 10
DP  - 2023
TI  - Drug-eluting beads bronchial arterial chemoembolization vs. conventional 
      bronchial arterial chemoembolization in the treatment of advanced non-small cell 
      lung cancer.
PG  - 1201468
LID - 10.3389/fmed.2023.1201468 [doi]
LID - 1201468
AB  - PURPOSE: To compare the effectiveness and safety of drug-eluting bead bronchial 
      artery chemoembolization (DEB-BACE) with conventional bronchial artery 
      chemoembolization (cBACE) and provide a novel treatment option for advanced 
      non-small cell lung cancer (NSCLC). METHODS: Patients with advanced NSCLC 
      underwent DEB-BACE or cBACE and were screened retrospectively. Progression-free 
      survival (PFS) and overall survival (OS) were the primary outcome indicators, 
      while technical success rate, objective response rate (ORR), disease control rate 
      (DCR), and adverse events (AEs) were the secondary ones. RESULTS: A total of 41 
      patients were enrolled in the study, 12 in the DEB-BACE group and 29 in the cBACE 
      group, according to the treatment regimen. No patient achieved complete response. 
      Eighteen patients achieved partial response (9 in each group), 15 patients 
      achieved stable disease (3 in the DEB-BACE group and 12 in the cBACE group), and 
      eight patients achieved progressive disease (all in the cBACE group) when treated 
      for 2 months. The overall ORR and DCR were 43.9% (18/41) and 80.5% (33/41), 
      respectively. ORR and DCR in the DEB-BACE group were 50.0% (9/12) and 100.0% 
      (12/12), respectively, while ORR and DCR in the cBACE group were 31.0% (9/29) and 
      72.4% (21/29), respectively. Compared to cBACE, the ORR and DCR of DEB-BACE were 
      significantly improved (p < 0.05). The median PFS was better in the DEB-BACE 
      group than in the cBACE group (6.95 months vs. 3.20 months, respectively, Hazard 
      Ratio [HR] = 0.416; p = 0.005). Furthermore, the median OS was significantly 
      better in the DEB-BACE group than in the cBACE group (28.5 months vs. 
      22.5 months, respectively, HR = 0.316; p = 0.020). CONCLUSION: DEB-BACE has a 
      good safety and therapeutic profile in advanced NSCLC and is superior to cBACE. 
      DEB-BACE can be used as an alternative treatment option for advanced NSCLC, even 
      in elderly patients.
CI  - Copyright (c) 2023 Yu, Shen, Chen, Xu and Yang.
FAU - Yu, Guocan
AU  - Yu G
AD  - Department of Thoracic Surgery, Affiliated Hangzhou Chest Hospital, Zhejiang 
      University School of Medicine, Hangzhou, Zhejiang, China.
FAU - Shen, Yanqin
AU  - Shen Y
AD  - Department of Nursing, Affiliated Hangzhou Chest Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang, China.
FAU - Chen, Liangliang
AU  - Chen L
AD  - Department of Thoracic Surgery, Affiliated Hangzhou Chest Hospital, Zhejiang 
      University School of Medicine, Hangzhou, Zhejiang, China.
FAU - Xu, Xudong
AU  - Xu X
AD  - Department of Thoracic Surgery, Affiliated Hangzhou Chest Hospital, Zhejiang 
      University School of Medicine, Hangzhou, Zhejiang, China.
FAU - Yang, Jun
AU  - Yang J
AD  - Department of Thoracic Surgery, Affiliated Hangzhou Chest Hospital, Zhejiang 
      University School of Medicine, Hangzhou, Zhejiang, China.
LA  - eng
PT  - Journal Article
DEP - 20230803
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC10435292
OTO - NOTNLM
OT  - BACE
OT  - DEB-BACE
OT  - NSCLC
OT  - PFS
OT  - disease control rate
OT  - objective response rate
OT  - os
OT  - safety
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/08/21 06:42
MHDA- 2023/08/21 06:43
PMCR- 2023/08/03
CRDT- 2023/08/21 05:06
PHST- 2023/04/06 00:00 [received]
PHST- 2023/07/24 00:00 [accepted]
PHST- 2023/08/21 06:43 [medline]
PHST- 2023/08/21 06:42 [pubmed]
PHST- 2023/08/21 05:06 [entrez]
PHST- 2023/08/03 00:00 [pmc-release]
AID - 10.3389/fmed.2023.1201468 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2023 Aug 3;10:1201468. doi: 10.3389/fmed.2023.1201468. 
      eCollection 2023.